Given the improved ability to spare heart, kidney and liver, should IMRT be the standard of care for gastric MALT lymphoma (despite the low dose needed to effectively treat these patients)?   

If so, what data should be presented to insurance companies to cover the cost?

Answer from: Radiation Oncologist at Academic Institution